157 related articles for article (PubMed ID: 21714932)
1. Relationship between hemoglobin A1c and cardiovascular disease in mild-to-moderate hypercholesterolemic Japanese individuals: subanalysis of a large-scale randomized controlled trial.
Nishimura R; Nakagami T; Sone H; Ohashi Y; Tajima N
Cardiovasc Diabetol; 2011 Jun; 10():58. PubMed ID: 21714932
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of LDL-C-related parameters to predict cardiovascular risk and effect of pravastatin in mild-to-moderate hypercholesterolemia.
Mizuno K; Nakaya N; Teramoto T; Yokoyama S; Ohashi Y; Ueki A; Takahashi S; Kubota Y; Nakamura H
J Atheroscler Thromb; 2012; 19(2):176-85. PubMed ID: 22129522
[TBL] [Abstract][Full Text] [Related]
3. Pravastatin reduces the risk for cardiovascular disease in Japanese hypercholesterolemic patients with impaired fasting glucose or diabetes: diabetes subanalysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study.
Tajima N; Kurata H; Nakaya N; Mizuno K; Ohashi Y; Kushiro T; Teramoto T; Uchiyama S; Nakamura H;
Atherosclerosis; 2008 Aug; 199(2):455-62. PubMed ID: 18635188
[TBL] [Abstract][Full Text] [Related]
4. Comparison of lipid parameters to predict cardiovascular events in Japanese mild-to-moderate hypercholesterolemic patients with and without type 2 diabetes: Subanalysis of the MEGA study.
Sone H; Nakagami T; Nishimura R; Tajima N;
Diabetes Res Clin Pract; 2016 Mar; 113():14-22. PubMed ID: 26972955
[TBL] [Abstract][Full Text] [Related]
5. Association between lowering low-density lipoprotein cholesterol with pravastatin and primary prevention of cardiovascular disease in mild to moderate hypercholesterolemic Japanese.
Teramoto T; Nakaya N; Yokoyama S; Ohashi Y; Mizuno K; Nakamura H;
J Atheroscler Thromb; 2010 Aug; 17(8):879-87. PubMed ID: 20543522
[TBL] [Abstract][Full Text] [Related]
6. Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study.
Kushiro T; Mizuno K; Nakaya N; Ohashi Y; Tajima N; Teramoto T; Uchiyama S; Nakamura H;
Hypertension; 2009 Feb; 53(2):135-41. PubMed ID: 19104004
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study).
Mizuno K; Nakaya N; Ohashi Y; Tajima N; Kushiro T; Teramoto T; Uchiyama S; Nakamura H;
Circulation; 2008 Jan; 117(4):494-502. PubMed ID: 18172039
[TBL] [Abstract][Full Text] [Related]
8. Low-dose pravastatin and age-related differences in risk factors for cardiovascular disease in hypercholesterolaemic Japanese: analysis of the management of elevated cholesterol in the primary prevention group of adult Japanese (MEGA study).
Nakaya N; Mizuno K; Ohashi Y; Teramoto T; Yokoyama S; Hirahara K; Mizutani M; Nakamura H;
Drugs Aging; 2011 Sep; 28(9):681-92. PubMed ID: 21815708
[TBL] [Abstract][Full Text] [Related]
9. Hemoglobin a1c levels and the risk of cardiovascular disease in people without known diabetes: a population-based cohort study in Japan.
Goto A; Noda M; Matsushita Y; Goto M; Kato M; Isogawa A; Takahashi Y; Kurotani K; Oba S; Nanri A; Mizoue T; Yamagishi K; Yatsuya H; Saito I; Kokubo Y; Sawada N; Inoue M; Iso H; Kadowaki T; Tsugane S;
Medicine (Baltimore); 2015 May; 94(17):e785. PubMed ID: 25929925
[TBL] [Abstract][Full Text] [Related]
10. Primary prevention of cardiovascular diseases among hypercholesterolemic Japanese with a low dose of pravastatin.
Nakamura H;
Atheroscler Suppl; 2007 Aug; 8(2):13-7. PubMed ID: 17586102
[TBL] [Abstract][Full Text] [Related]
11. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
JAMA; 2002 Dec; 288(23):2998-3007. PubMed ID: 12479764
[TBL] [Abstract][Full Text] [Related]
12. The Combination of Elevated Triglycerides and Abnormal Fasting Glucose Increases Risk of Cerebral Infarction in Patients With Mild to Moderate Hypercholesterolemia: A Post Hoc Analysis of the MEGA Study.
Nakagami T; Nishimura R; Sone H; Tajima N
J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):169-73. PubMed ID: 24906541
[TBL] [Abstract][Full Text] [Related]
13. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
[TBL] [Abstract][Full Text] [Related]
14. Suboptimal control of lipid levels: results from the non-interventional Centralized Pan-Russian Survey of the Undertreatment of Hypercholesterolemia II (CEPHEUS II).
Boytsov S; Logunova N; Khomitskaya Y;
Cardiovasc Diabetol; 2017 Dec; 16(1):158. PubMed ID: 29246151
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: analysis of data from the MEGA Study, a large randomized controlled trial.
Uchiyama S; Nakaya N; Mizuno K; Ohashi Y; Tajima N; Kushiro T; Teramoto T; Nakamura H;
J Neurol Sci; 2009 Sep; 284(1-2):72-6. PubMed ID: 19423132
[TBL] [Abstract][Full Text] [Related]
16. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial.
Nakamura H; Arakawa K; Itakura H; Kitabatake A; Goto Y; Toyota T; Nakaya N; Nishimoto S; Muranaka M; Yamamoto A; Mizuno K; Ohashi Y;
Lancet; 2006 Sep; 368(9542):1155-63. PubMed ID: 17011942
[TBL] [Abstract][Full Text] [Related]
17. The relationship between low-density lipoprotein cholesterol levels and the incidence of cardiovascular disease in high-risk patients treated with pravastatin: main results of the APPROACH-J study.
Daida H; Teramoto T; Kitagawa Y; Matsushita Y; Sugihara M
Int Heart J; 2014; 55(1):39-47. PubMed ID: 24463915
[TBL] [Abstract][Full Text] [Related]
18. Association Between Hemoglobin A1c and Development of Cardiovascular Disease in Canadian Men and Women Without Diabetes at Baseline: A Population-Based Study of 608 474 Adults.
Butalia S; Chu LM; Dover DC; Lau D; Yeung RO; Eurich DT; Senior P; Kaul P
J Am Heart Assoc; 2024 May; 13(9):e031095. PubMed ID: 38639364
[TBL] [Abstract][Full Text] [Related]
19. The effect of 6 months of treatment with pravastatin on serum adiponection concentrations in Japanese patients with coronary artery disease and hypercholesterolemia: a pilot study.
Sakamoto K; Sakamoto T; Ogawa H;
Clin Ther; 2006 Jul; 28(7):1012-21. PubMed ID: 16990079
[TBL] [Abstract][Full Text] [Related]
20. The effect of low-dose pravastatin in metabolic syndrome for primary prevention of cardiovascular disease in Japan: a post hoc analysis of the MEGA study.
Matsushima T; Nakaya N; Mizuno K; Ohashi Y; Teramoto T; Yokoyama S; Ichikawa S; Ishikura N; Kamiyama K; Nakamura H;
J Cardiovasc Pharmacol Ther; 2012 Jun; 17(2):153-8. PubMed ID: 22573644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
